For example, in clinical practice, patients with EGFR-mutant NSCLC have shown substantial tumor shrinkage after neoadjuvant EGFR inhibition, facilitating less extensive surgical resections [8]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.